- Home
- STTK vs CLST Comparison
STTK vs CLST Comparison
Compare STTK & CLST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CLST
- Stock Information
- Founded
- STTK 2016
- CLST 1922
- Country
- STTK United States
- CLST United States
- Employees
- STTK N/A
- CLST N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CLST
- Sector
- STTK Health Care
- CLST
- Exchange
- STTK Nasdaq
- CLST Nasdaq
- Market Cap
- STTK 56.8M
- CLST 51.0M
- IPO Year
- STTK 2020
- CLST N/A
- Fundamental
- Price
- STTK $1.37
- CLST $11.72
- Analyst Decision
- STTK Hold
- CLST
- Analyst Count
- STTK 3
- CLST 0
- Target Price
- STTK $2.00
- CLST N/A
- AVG Volume (30 Days)
- STTK 131.9K
- CLST 4.3K
- Earning Date
- STTK 03-03-2025
- CLST 01-23-2025
- Dividend Yield
- STTK N/A
- CLST N/A
- EPS Growth
- STTK N/A
- CLST N/A
- EPS
- STTK N/A
- CLST N/A
- Revenue
- STTK $6,435,000.00
- CLST $5,174,000.00
- Revenue This Year
- STTK $313.04
- CLST N/A
- Revenue Next Year
- STTK N/A
- CLST N/A
- P/E Ratio
- STTK N/A
- CLST N/A
- Revenue Growth
- STTK 382.75
- CLST N/A
- 52 Week Low
- STTK $0.94
- CLST $10.78
- 52 Week High
- STTK $11.76
- CLST $12.10
- Technical
- Relative Strength Index (RSI)
- STTK 60.23
- CLST 51.74
- Support Level
- STTK $1.21
- CLST $11.68
- Resistance Level
- STTK $1.36
- CLST $11.75
- Average True Range (ATR)
- STTK 0.10
- CLST 0.05
- MACD
- STTK 0.01
- CLST 0.00
- Stochastic Oscillator
- STTK 90.00
- CLST 75.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About CLST Catalyst Bancorp Inc.
Catalyst Bancorp Inc is a federally chartered community-oriented savings bank. The bank is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources which are used for the origination of loans. The Bank derives its income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.